Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Medtronic
UBS
QuintilesIMS
Cipla
Harvard Business School
Baxter
Johnson and Johnson

Generated: December 16, 2018

DrugPatentWatch Database Preview

Litigation Details for In re: Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (D. Del. 2009)

« Back to Dashboard

In re: Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (D. Del. 2009)

Docket ➤ Sign Up Date Filed 2009-12-02
Court District Court, D. Delaware Date Terminated 2014-09-24
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand Defendant Referred To
Parties ANCHEN INC.; ANCHEN PHARMACEUTICALS INC.; ANESTA AG; APTALIS PHARMATECH INC.; BARR LABORATORIES INC.; CEPHALON INC.; CLERK JEFFERY N. LUTHI; CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION; EURAND INC.; IMPAX LABORATORIES INC.; IVAX INTERNATIONAL GMBH; MYLAN INC.; MYLAN PHARMACEUTICALS INC.; PAR PHARMACEUTICAL INC.; TWI PHARMACEUTICALS INC.
Patents 6,344,215; 7,387,793; 7,544,372; 7,790,199; 7,820,203; 7,829,121
Attorneys Artemio C. Aranilla , II; Bindu Ann George Palapura; Brian E. Farnan; Brian H. Pandya; C. Kyle Musgrove; Dana Kathryn Severance; Daralyn J. Durie; David Ellis Moore; Debbie McComas; Don J. Mizerk; Donald Mizerk; Douglas Edward McCann; James H. Wallace , Jr.; Jeffery N. Luthi; Jeffrey L. Moyer; Jennifer Lynn Hall; Jennifer Lynne Hall; John A. Sholar; John C. Phillips , Jr.; John R. Lane; Jonathan E. Singer; Joseph Benedict Cicero; Joseph S. Shannon; Julia Johnson; Karin A. Hessler; Kelly E. Farnan; Mark A. Pacella; Mary Matterer; Mary W. Bourke; Matthew J. Dowd; Maureen L. Rurka; Megan C. Haney; Michael M. Shen; Paul Damon Brown; Richard L. Horwitz; Robert J. Scheffel; Robert M. Oakes; Susan Morrison Coletti; Tryn T. Stimart; William J. Marsden , Jr.
Firms Clerk, MDL Judicial Panel; Farnan LLP; Husch Blackwell Sanders Welsh & Katz; Phillips, Goldman & Spence, P.A.; Richards, Layton & Finger, PA; Winston and Strawn; Womble Carlyle Sandridge & Rice, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in In re: Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up and ➤ Sign Up .

Details for In re: Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2009-12-02 1 Order 2 U.S. Patent Nos. 7,387,793 and 7,544,372. Case 1:09-md-02118-SLR…CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION …parties and the courts. See In re Brimonidine Patent Litigation, 507 F.Supp.2d 1381, 1382 (J.P.M.L. …CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION …Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation 2 December 2009 24 External link to document
2010-09-24 211 Order dispute involving newly issued U.S. Patent No. 7,790,199 as that patent is or may be asserted against defendants…Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation 2 December 2009 24…24 September 2014 1:09-md-02118 830 Patent Defendant District Court, D. Delaware External link to document
2010-10-29 227 Stipulation and/or invalidity with respect to U.S. Patent Nos. 7,387,793 and 7,544,372, whichever date is earlier…Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation 2 December 2009 24…24 September 2014 1:09-md-02118 830 Patent Defendant District Court, D. Delaware External link to document
2010-11-18 236 Stipulation STIPULATION re 7,790,199; 7,820,203; and 7,829,121 patents by Anesta AG, Cephalon Inc., Eurand …Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation 2 December 2009 24…24 September 2014 1:09-md-02118 830 Patent Defendant District Court, D. Delaware External link to document
2010-03-12 25 Memorandum Opinion 7,2009 for infringement of U.S. Patent No. 7,387,793 ("the '793 patent"). (0.1. 1)3 Anchen Pharmaceuticals… in the '793 patent and the '372 patent (collectively, lithe Eurand patents"). (Civ. No.… the infringement of U.S. Patent No. 7,544,372 ("the '372 patent"). (Civ. No. 09-715-SLR…quot;) lists, inter alia, the Eurand patents as the unexpired patents associated with AMRIX®. (/d. at 22…#39;793 patent. (0.1. 22, ex. 3) Anchen Pharmaceuticals further alleged that the '793 patent was invalid External link to document
2011-05-12 254 Opinion European Patent Application No. 92109699.6 to Urban ("Urban"), and US Patent No. 6,344,215 ("… U.S. Patent Nos. 7,387,793 (lithe '793 patent") and 7,544,372 (lithe '372 patent"… for its use. The '372 patent is a divisional patent of the 793 patent, and shares both its specification…of the patents-in-suit, is also a named inventor on the '215 patent and the '215 patent forms …;215 patent was material to the prosecution of the '793 patent because the '215 patent is directed External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Dow
Queensland Health
Argus Health
US Army
UBS
Cerilliant
Baxter
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.